Absorption of three wine-related polyphenols in three different matrices by healthy subjects

Clinical Biochemistry

Volumn 36, Issue 1, 2003, Pages 79-87

  Goldberg, David M ^b   Yan, Joseph ^a   Soleas, George J ^a  

^a Quality Assurance Laboratory   (Canada)

^b NONE

Author keywords

Absorption; Bioavailability; Ethanol; Gas chromatography; Glucuronidation; Grape juice; Pharmacokinetics; Quercetin; Sulfation; trans Resveratrol; Wine; + Catechin

Indexed keywords

ALCOHOL; CATECHIN; GLUCURONIDE; POLYPHENOL DERIVATIVE; QUERCETIN; RESVERATROL; SULFATE;

ADULT; AGE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONJUGATE; CONTROLLED STUDY; DOSE CALCULATION; FOOD INTAKE; GAS CHROMATOGRAPHY; GENDER; GRAPE JUICE; HEALTH STATUS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INTESTINE ABSORPTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TIME; URINALYSIS; URINARY EXCRETION; URINE LEVEL; VEGETABLE; WINE;

EID: 0037248470     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00397-1     Document Type: Article

References (67)

1. Goldberg D.M., Soleas G.J., Levesque M. Moderate alcohol consumption The gentle face of Janus. Clin Biochem. 32:1999;505-518.
2. Meister K.A., Whelan E.M., Kava R. The health effects of moderate alcohol intake in humans an epidemiologic review. Crit Rev Clin Lab Sci. 37:2000;261-296.
3. Criqui M.H. Alcohol and coronary heart disease consistent relationship and public health implications. Clin Chim Acta. 246:1996;51-57.
4. Rubin R., Rand M.L. Alcohol and platelet function. Alcohol Clin Exp Res. 18:1994;105-109.
5. Booyse F.M., Aikens M.L., Grenett H.E. Endothelial cell fibrinolysis transcriptional regulation of fibrinolytic protein gene expression (t-PA, u-PA, and AI-1) by low alcohol. Alcohol Clin Exp Res. 23:1999;1119-1124.
6. Locher R., Suter P.M., Vetter W. Ethanol suppresses smooth muscle cell proliferation in the postprandial state a new antiatherosclerotic mechanism of ethanol? Am J Clin Nutr. 67:1998;338-341.
7. Goldberg D.M., Soleas G.J. Beverage alcohol consumption as a negative risk factor for coronary heart disease: Biochemical mechanisms. Agarwal D.P., Seitz H.K. Alcohol in Health and Disease. 2001;547-572 Marcel Dekker, Inc, NY.
8. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 339:1992;1523-1526.
9. Rimm E.B., Klatsky A., Grobbee D., Stampfer M.J. Review of moderate alcohol consumption and reduced risk of coronary heart disease is the effect due to beer, wine, or spirits. BMJ. 312:1999;731-736.
10. Klurfeld D.M., Kritchevsky D. Differential effects of alcoholic beverages on experimental atherosclerosis in rabbits. Exp Mol Pathol. 34:1981;62-71.
11. Munday J.S., Thompson K.G., James K.A., Manktelow B.W. The effect of moderate alcohol consumption as either red or white wine in the C57BL/6 mouse atherosclerosis model. Coron Artery Dis. 10:1999;97-102.
12. Wakabayashi Y. Effect of red wine consumption on low-density lipoprotein oxidation and atherosclerosis in aorta and coronary artery in Watanabe heritable hyperlipidemic rabbits. J Agric Food Chem. 47:1999;4724-4730.
13. Kanner J., Frankel E., Granit R., German B., Kinsella J.E. Natural antioxidants in grapes and wines. J Agric Food Chem. 42:1994;64-69.
14. Soleas G.J., Diamandis E.P., Goldberg D.M. Wine as a biological fluid history, production, and role in disease prevention. J Clin Lab Anal. 11:1997;287-313.
15. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis implications for protection against coronary heart disease. Clin Chim Acta. 235:1995;207-219.
16. Fuhrman B., Lavy A., Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr. 61:1995;549-554.
17. Miyagi Y., Miwa K., Inoue H. Inhibition of human low-density lipoprotein oxidation by flavonoids in red wine and grape juice. Am J Cardiol. 80:1997;1627-1631.
18. Nigdikar S.V., Williams N.R., Griffin B.A., Howard A.N. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr. 68:1998;258-265.
19. van Golde P.H., Sloots L.M., Vermeulen W.P., Wielders J.P., Hart H.C., Bouma B.N., van de Wiel A. The role of alcohol in the anti low-density lipoprotein oxidation activity of red wine. Atherosclerosis. 147:1999;365-370.
20. de Rijke Y.B., Demacker P.N., Assen N.A., Sloots L.M., Katan M.B., Stalenhoef A.F. Red wine consumption does not affect oxidizability of low-density lipoproteins in volunteers. Am J Clin Nutr. 63:1996;329-334.
21. Caccetta R.A., Croft K.D., Beilin L.J., Puddey I.B. Ingestion of red wine significantly increases plasma phenolic acid concentrations but does not acutely affect ex vivo lipoprotein oxidizability. Am J Clin Nutr. 71:2000;67-74.
22. Goldberg D.M., Garovic-Kocic V., Diamandis E.P., Pace-Asciak C.R. Winesdoes the colour count? Clin Chim Acta. 246:1996;183-193.
23. Pace-Asciak C.R., Rounova O., Hahn S.E., Diamandis E.P., Goldberg D.M. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta. 246:1996;163-182.
24. Ruf J.C., Berger J.L., Renaud S. Platelet rebound effect of alcohol withdrawal and wine drinking in rats. Relation to tannins and lipid peroxidation. Arterioscler Thromb Vasc Biol. 15:1995;140-144.
25. Bertelli A.A.E., Giovannini L., Stradi R., Urien S., Tillement J.-P., Bertelli A. Kinetics of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharm Res. 16:1996;77-81.
26. Bertelli A.A.E., Giovannini L., Stradi R., Bertelli A., Tillement J.-P. Plasma, urine and tissue levels of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tiss Reac. 18:1996;67-71.
27. Soleas G.J., Angelini M., Grass L., Diamandis E.P., Goldberg D.M. Absorption of trans-Resveratrol in rats. Methods Enzymol. 335:2001;145-154.
28. Soleas G.J., Yan J., Goldberg D.M. Measurement of trans-resveratrol, (+)-catechin, and quercetin in rat and human blood and urine by gas chromatography with mass selective detection. Methods Enzymol. 335:2001;130-145.
29. Kuhnle G., Spencer J.P., Chowrimootoo G., Schroeter H., Debnam E.S., Srai S.K., Rice-Evans C., Hahn U. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun. 272:2000;212-217.
30. Andlauer W., Kolb J., Siebert K., Furst P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res. 26:2000;47-55.
31. De Santi C., Pietrabissa A., Spisni R., Mosca F., Pacifici G.M. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica. 30:2000;609-617.
32. Soleas G.J., Yan J., Goldberg D.M. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B. 757:2001;161-172.
33. Donovan J.L., Crespy V., Manach C., Morand C., Besson C., Scalbert A., Remesy C. Catechin is metabolized by both the small intestine and liver of rats. J Nutr. 131:2001;1753-1757.
34. Baba S., Osakabe N., Natsume M., Muto Y., Takizawa T., Terao J. In vivo comparison of the bioavailability of (+)-catechin, (-)-epicatechin and their mixture in orally administered rats. J Nutr. 131:2001;2885-2891.
35. Donovan J.L., Bell J.R., Kasim-Karakas S., German J.B., Walzem R.L., Hansen R.J., Waterhouse A.L. Catechin is present as metabolites in human plasma after consumption of red wine. J Nutr. 129:1999;1662-1668.
36. Bell J.R., Donovan J.L., Wong R., Waterhouse A.L., German J.B., Walzem R.L., Kasim-Karakas S.E. (+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. Am J Clin Nutr. 71:2000;103-108.
37. Manach C., Morand C., Texier O., Favier M.L., Agullo G., Demigne C., Regerat F., Remesy C. Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin. J Nutr. 125:1995;1911-1922.
38. Manach C., Morand C., Demigne C., Texier O., Regerat F., Remesy C. Bioavailability of rutin and quercetin in rats. FEBS Lett. 409:1997;12-16.
39. Morand C., Crespy V., Manach C., Besson C., Demigne C., Remesy C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol. 275:1998;R212-219.
40. Crespy V., Morand C., Manach C., Besson C., Demigne C., Remesy C. Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am J Physiol. 277:1999;G120-G126.
41. Hollman P.C.H., de Vries J.H.M., van Leeuwen S.D., Mengelers M.J.B., Katan M.B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr. 62:1995;1276-1282.
42. Hollman P.C.H., Gaag M.V.D., Mengelers M.J.B., van Trijp J.M.P., De Vries J.H.M., Katan M.B. Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic Biol Med. 3:1996;703-707.
43. Hollman P.C.H., van Trijp J.M.P., Buysman M.N.C.P., Gaag M.S.V.D., Mengelers M.J.B., de Vries J.H.M., Katan M.B. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 418:1997;152-156.
44. De Vries J.H.M., Hollman P.C.H., Meyboom S., Buysman M.N.C.P., Zock P.L., van Staveren W.A., Katan M.B. Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am J Clin Nutr. 68:1998;60-65.
45. Day A.J., Williamson G. Biomarkers for exposure to dietary flavonoids a review of the current evidence for identification of quercetin glycosides in plasma. Br J Nutr. 86:2001;S105-110.
46. Morand C., Manach C., Crespy V., Remesy C. Quercetin 3-O-beta-glucoside is better absorbed than other quercetin forms and is not present in rat plasma. Free Radic Res. 33:2000;667-676.
47. Asensi M., Medina I., Ortega A., Carretero J., Bano M.C., Obrador E., Estrela J.M. Inhibition of cancer growth by resveratrol is limited by its low bioavailability. Free Radic Med Biol. 33:2002;387-398.
48. Donovan J.L., Luthria D.L., Stremple P., Waterhouse A.L. Analysis of (+)-catechin, (-)-epicatechin and their 3′- and 4′-O-methylated analogs. A comparison of sensitive methods. J Chromatogr B. 726:1999;277-283.
49. Das N.P., Sothy S.P. Studies on flavonoid metabolism. Biliary and urinary excretion of metabolites of (+)-(U- 14C)catechin. Biochem J. 125:1971;417-423.
50. Graef E.U., Wittig J., Mueller S., Riethling A.K., Uehleke B., Drewelow B., Pforte H., Jacobasch G., Derendorf H., Veit M. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol. 41:2001;492-499.
51. Ader P., Wessmann A., Wolffram S. Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic Biol Med. 28:2000;1056-1067.
52. Sesink A.L., O'Leary K.A., Hollman P.C. Quercetin glucuronides but not glucosides are present in human plasma after consumption of quercetin-2-glucoside or quercetin-4′-glucoside. J Nutr. 131:2001;1938-1941.
53. Walle T., Walle U.K., Halushka P.V. Carbon dioxide is the major metabolite of quercetin in humans. J Nutr. 131:2001;2648-2652.
54. Terao J. Dietary flavonoids as antioxidants in vivo conjugated metabolites of (-)-epicatechin, and quercetin participate in antioxidative defense in blood plasma. J Med Invest. 46:1999;159-168.
55. Moon J., Tsushida T., Nakahara K., Terao J. Identification of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med. 30:2001;1274-1285.
56. Koga T., Meydani M. Effect of plasma metabolites of (+)-catechin and quercetin on monocyte adhesion to human aortic endothelial cells. Am J Clin Nutr. 73:2001;941-948.
57. Maxwell S., Cruickshank A., Thorpe G. Red wine and antioxidant activity in serum. Lancet. 344:1994;1152.
58. Whitehead T.P., Robinson D., Allaway S., Syms J., Hale A. Effect of red wine ingestion on the antioxidant capacity of serum. Clin Chem. 41:1995;32-35.
59. Maxwell S.R.J. Wine antioxidants and their impact on antioxidant activity in vivo. Watkins T.R. Wine-nutritional and therapeutic benefits. 1997;155-165 Am Chem Society, Washington, DC.
60. Lavy A., Fuhrman B., Market A., Dankner G., Ben-Amotz A., Presser D., Aviram M. Effect of dietary supplementation of red or white wine on human blood chemistry, hematology and coagulation favorable effect of red wine on plasma high-density lipoprotein. Ann Nutr Metab. 38:1994;287-294.
61. Janssen K., Mensink R.P., Cox F.J., Harryvan J.L., Hovenier R., Hollman P.C., Katan M.B. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers results from an in vitro and a dietary supplement study. Am J Clin Nutr. 67:1998;255-262.
62. Agewall S., Wright S., Doughty R.N., Whalley G.A., Duxbury M., Sharpe N. Does a glass of red wine improve endothelial function? Eur Heart J. 21:2000;74-78.
63. Senault C., Betoulle D., Luc G., Hauw P., Rigaud D., Fumeron F. Beneficial effects of a moderate consumption of red wine on cellular cholesterol efflux in young men. Nutr Metab Cardiovasc Dis. 10:2000;63-69.
64. Feng AN, Chen YL, Chen YT, Ding YZ, Lin SJ. Red wine inhibits monocyte chemotactic protein-1 expression and modestly reduces neointimal hyperplasia after balloon injury in cholesterol-fed rabbits.
65. Sato M., Ray P.S., Maulik G., Maulik N., Engelman R.M., Bertelli A.A., Bertelli A., Das D.K. Myocardial protection with red wine extract. J Cardiovasc Pharmacol. 35:2000;263-268.
66. Soleas G.J., Diamandis E.P., Goldberg D.M. The World of Resveratrol. Adv Exp Med Biol. 492:2000;159-182.
67. de Vries J.H., Hollman P.C., van Amersfoort I., Olthof M.R., Katan M.B. Red wine is a poor source of bioavailable flavonols in men. J Nutr. 131:2001;745-748.